Alpha Cognition Inc
Alpha Cognition Inc. is a commercial-stage biopharmaceutical company based in Vancouver, BC, focused on developing treatments for patients suffering from neurodegenerative diseases, including Alzheimer's disease and cognitive impairment related to mild traumatic brain injury. Its lead product, ZUNVEYL (galantamine), is a cholinesterase inhibitor approved for the treatment of mild to moderate dementia of the Alzheimer's type in adults.
The company is committed to addressing the challenges of limited treatment options available for such debilitating conditions and actively engages in research and development to advance its pipeline. Alpha Cognition also emphasizes the importance of safety and patient monitoring in its therapeutic approach, reflecting its dedication to improving the lives of those affected by neurodegenerative diseases.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.